Compare Crispr Therapeutics AG (CRSP) vs Devon Energy Corp (DVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Devon Energy Corp — how do they compare? Crispr Therapeutics AG trades at $53.51 (market cap $4.88B), while Devon Energy Corp trades at $48.26 (market cap $53.81B). The key difference: Devon Energy Corp is far larger — about 11× Crispr Therapeutics AG's market cap, and Devon Energy Corp pays a 2.62% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Devon Energy Corp for 136 Days on average.
| CRSP | DVN | |
|---|---|---|
Market Cap | $4.88B | $53.81B |
Volume | 2,861,747 | 11,556,740 |
Sector | Health | Energy |
52-Week High | $74.92 | $52.07 |
52-Week Low | $44.34 | $31.74 |
Typical Hold Time | 77 Days | 136 Days |
Enterprise Value | $3.30B | $64.55B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
Devon Energy (DVN) trades at $48.26, up 0.79% with a bullish technical outlook. The stock shows strong fundamentals with a P/E of 10.63 and net margin of 16.67%, supported by recent earnings beats. Analyst consensus is strongly bullish with a $62.53 price target, representing 30% upside potential. Recent news highlights activist investor pressure for strategic alternatives including potential sale, while BP shows interest in acquiring Eagle Ford assets.
DVN presents compelling value with attractive valuation metrics and solid profitability. Key opportunities include potential asset sales and Permian Basin strength, while risks involve oil price volatility and execution of strategic initiatives. The stock's current valuation discount to analyst targets suggests significant upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
